Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-09 11:16 am Sale | 2022-12-30 | 13G | CytomX Therapeutics, Inc. CTMX | The Vanguard Group | 4,585,721 6.940% | -522,270 (-10.22%) | Filing History |
| 2022-07-29 4:37 pm Purchase | 2022-07-27 | 13G | CytomX Therapeutics, Inc. CTMX | BIOTECHNOLOGY VALUE FUND L P | 6,595,801 10.100% | 792,101 (+13.65%) | Filing History |
| 2022-07-25 4:00 pm Purchase | 2022-07-15 | 13G | CytomX Therapeutics, Inc. CTMX | TANG CAPITAL PARTNERS LP | 3,470,900 5.300% | 3,470,900 (New Position) | Filing History |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | CytomX Therapeutics, Inc. CTMX | BlackRock Inc. BLK | 1,826,591 2.800% | -3,135,771 (-63.19%) | Filing History |
| 2022-02-14 4:43 pm Purchase | 2021-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | Point72 Asset Management, L.P. | 6,312,371 9.700% | 788,465 (+14.27%) | Filing History |
| 2022-02-14 4:11 pm Sale | 2021-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | RA Capital Management, L.P. | 0 0.000% | -3,500,000 (Position Closed) | Filing History |
| 2022-02-14 08:58 am Purchase | 2021-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | RTW Investments, LP | 6,029,700 9.200% | 161,374 (+2.75%) | Filing History |
| 2022-02-09 3:43 pm Purchase | 2021-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | The Vanguard Group | 5,107,991 7.830% | 2,173,567 (+74.07%) | Filing History |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | BlackRock Inc. BLK | 4,962,362 7.600% | 1,157,183 (+30.41%) | Filing History |
| 2022-02-01 12:25 pm Sale | 2021-12-31 | 13G | Cryoport, Inc. CYRX | VICTORY CAPITAL MANAGEMENT INC | 8,828 0.010% | -2,719,209 (-99.68%) | Filing History |
| 2022-01-03 4:34 pm Purchase | 2021-12-21 | 13G | CytomX Therapeutics, Inc. CTMX | BIOTECHNOLOGY VALUE FUND L P | 5,803,700 8.900% | 2,884,229 (+98.79%) | Filing History |
| 2021-12-08 2:06 pm Purchase | 2021-11-29 | 13G | CytomX Therapeutics, Inc. CTMX | RTW Investments, LP | 5,868,326 8.990% | 5,868,326 (New Position) | Filing History |
| 2021-05-03 5:19 pm Sale | 2021-04-29 | 13G | CytomX Therapeutics, Inc. CTMX | BIOTECHNOLOGY VALUE FUND L P | 2,919,471 4.500% | -2,657,000 (-47.65%) | Filing History |
| 2021-02-16 3:57 pm Sale | 2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | Perceptive Advisors LLC | 2,577,043 4.300% | -676,880 (-20.80%) | Filing History |
| 2021-02-11 5:27 pm Purchase | 2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | BIOTECHNOLOGY VALUE FUND L P | 5,576,471 12.100% | 950,060 (+20.54%) | Filing History |
| 2021-02-10 10:46 am Purchase | 2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | The Vanguard Group | 2,934,424 6.350% | 244,820 (+9.10%) | Filing History |
| 2021-02-02 3:13 pm Sale | 2020-12-31 | 13G | Cryoport, Inc. CYRX | VICTORY CAPITAL MANAGEMENT INC | 2,728,037 7.110% | -85,414 (-3.04%) | Filing History |
| 2021-01-29 4:30 pm Purchase | 2021-01-29 | 13G | CytomX Therapeutics, Inc. CTMX | RA Capital Management, L.P. | 3,500,000 5.800% | 3,500,000 (New Position) | Filing History |
| 2021-01-29 09:56 am Sale | 2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | BlackRock Inc. BLK | 3,805,179 8.200% | -210,869 (-5.25%) | Filing History |
| 2021-01-26 5:20 pm Purchase | 2021-01-25 | 13G | CytomX Therapeutics, Inc. CTMX | Point72 Asset Management, L.P. | 5,523,906 9.100% | 5,523,906 (New Position) | Filing History |